Reset Pharma – Reset Pharma

Nov 01 2023

Reset Pharma Receives Notice of Safe to Proceed from FDA for Investigational New Drug (IND) Application for Oral Psilocybin RSTP1000

By Reset Pharma Press Release

Company may now initiate Phase 2b trial for treatment of demoralization syndrome in patients with cancer Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development…

Nov 02 2022

Love0

Reset Pharmaceuticals Announces Appointment of Neuroscience Industry Leader Lisa Deschamps to the Board of Directors

By Reset Pharma Press Release

Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development and commercialization of novel clinical-stage treatments for patients suffering from mental illnesses related to life-altering diseases,…

Oct 14 2021

Love0

Stephen Ross, M.D., Chair of Reset Pharma’s Scientific Advisory Board to Deliver Keynote Presentation at The End in Mind Virtual Conference

By Reset Pharma Press Release

Reset Pharmaceuticals, Inc. (Reset Pharma) announced today that Stephen Ross, M.D., Chair of Reset Pharma’s Scientific Advisory Board, will deliver a keynote presentation at The End in Mind virtual conference…

Aug 08 2021

Love0

End-Of-Life Care Is The New Frontier In Psychedelic-Assisted Therapy [via Forbes]

https://www.forbes.com/sites/benjaminadams/2021/09/24/the-end-in-mind-conference-answers-questions-about-psychedelics-for-end-of-life-patients/

Jul 07 2021

Love0

Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer

By Reset Pharma Press Release

Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in psychedelics, named chair of…